- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US | ||
| Fr | CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval | ||
| Fr | Alexion and NICE agree confidential discount for Ultomiris use on the NHS | ||
| Fr | Novartis' MS therapy Kesimpta reduces risk of disability progression regardless of relapses | ||
| Fr | Virtually, the same: Is it time to rethink congress strategy? | ||
| Do | Merck & Co halts development of potential COVID-19 drug MK-7110 | ||
| Do | Making social sexy | ||
| Do | McCann Health UK appoints Jonathan Kukathasan as president | ||
| Do | Indigo Medical joins imc group | ||
| Do | GSK discontinues two feladilimab trials in head and neck cancer | ||
| Do | European Commission approves Opdivo plus Cambometyx for advanced kidney cancer | ||
| Do | Novartis agrees to help produce Roche's repurposed COVID-19 drug | ||
| Do | UPDATE: US pauses rollout of J&J's COVID-19 vaccine amid reports of rare blood clots | ||
| Do | From if to how: when imagination and regulation work together | ||
| Mi | BeiGene, Novartis's PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC | ||
| Mi | Saturnino Izquierdo takes on expanded role at McCann Health | ||
| Mi | J&J delays EU COVID-19 vaccine rollout following pause in the US | ||
| Mi | Moderna's booster vaccine for South African variant demonstrates promising early results | ||
| Mi | UK trial evaluating mixed-vaccine regimens includes two more jabs | ||
| Mi | Follow the user - democratising medical conference design | ||
| Di | US pauses rollout of J&J's COVID-19 vaccine amid reports of rare blood clots | ||
| Di | Lilly's RET inhibitor Retevmo shows early promise in new cancer types | ||
| Di | Oxford study finds standard asthma medication improves recovery time in COVID-19 patients | ||
| Di | FDA approves new self-injection administration for Xolair | ||
| Di | Scientific meetings: leveraging on-site, virtual, on-demand and enduring materials |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
